Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Zingg D, et al. Among authors: van de ven m, van gerwen b, van der burg e, van miltenburg mh. Nature. 2022 Aug;608(7923):609-617. doi: 10.1038/s41586-022-05066-5. Epub 2022 Aug 10. Nature. 2022. PMID: 35948633 Free PMC article. Clinical Trial.
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J. Evers B, et al. Among authors: van der burg e, van drunen e. Clin Cancer Res. 2008 Jun 15;14(12):3916-25. doi: 10.1158/1078-0432.CCR-07-4953. Clin Cancer Res. 2008. PMID: 18559613 Free article.
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J. Rottenberg S, et al. Among authors: van der burg e. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29. Proc Natl Acad Sci U S A. 2008. PMID: 18971340 Free PMC article.
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P, Rottenberg S. Zander SA, et al. Among authors: van der burg e, van tellingen o. Cancer Res. 2010 Feb 15;70(4):1700-10. doi: 10.1158/0008-5472.CAN-09-3367. Epub 2010 Feb 9. Cancer Res. 2010. PMID: 20145144
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P. Rottenberg S, et al. Among authors: van der burg e. Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6. Cancer Res. 2012. PMID: 22396490 Free PMC article.
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Groenendijk FH, Mellema WW, van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel MM, Jonkers J, Smit EF, Bernards R. Groenendijk FH, et al. Among authors: van der burg e, van den heuvel mm. Int J Cancer. 2015 Mar 15;136(6):1434-44. doi: 10.1002/ijc.29113. Epub 2014 Aug 8. Int J Cancer. 2015. PMID: 25080865 Free PMC article. Clinical Trial.
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Józwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J. Ter Brugge P, et al. Among authors: van der burg e, van roosmalen m. J Natl Cancer Inst. 2016 Jul 5;108(11). doi: 10.1093/jnci/djw148. Print 2016 Nov. J Natl Cancer Inst. 2016. PMID: 27381626
102 results